Re-Opening NJ Post COVID-19: What Biopharmaceutical Companies Need
The COVID-19 pandemic has disrupted the American way of life in many ways. From school closings to shelter in place orders, we have all needed to adapt to do our part to help “flatten the curve” of the Coronavirus. And the human toll of the pandemic – more than 1,000,000 Patients and thousands of deaths – has been unimaginable.
Here in New Jersey, employers and employees are finding new and creative ways to continue operations. Some segments of the economy have needed to develop new policies for operations in the face of mandated and necessary social distancing policies. For New Jersey’s research and development life sciences ecosystem, continuing to operate safely was necessary to deliver the lifesaving treatments the world has come to expect from the Garden State. New Jersey leads the nation in biopharmaceutical manufacturing, supplying critical Patient treatments in oncology, cell and gene therapy and many rare disease states. Continued safe manufacturing operations have helped ensure that Patients around the country can continue accessing the treatments they need when they need them most – even in the face of a global pandemic.
Still, questions remain for the State’s biopharmaceutical sector as New Jersey looks to safely “re-open” the State’s economy. BioNJ recently surveyed the State’s life sciences community to help provide a more complete picture of re-opening needs. The results of this survey show that there are unique re-opening concerns for New Jersey’s biopharmaceutical industry.
Click here
for BioNJ's report and recommendations.
